

References

I-7

1. Inrig JK, Barnhart HX, Reddan D et al. Effect of hemoglobin target on progression of kidney disease: a secondary analysis of the CHOIR (Correction of Hemoglobin and Outcomes in Renal Insufficiency) trial. *Am J Kidney Dis.* 2012; 60(3):390-401.
2. Skali H, Parving HH, Parfrey PS et al. Stroke in patients with type 2 diabetes mellitus, chronic kidney disease, and anemia treated with darbepoetin alfa: the trial to reduce cardiovascular events with Aranesp therapy (TREAT) experience. *Circulation.* 2011; 124(25):2903-8.
3. Macdougall IC, Wiecek A, Tucker B, et al. Dose-finding study of peginesatide for anemia correction in chronic kidney disease patients. *Clin J Am Soc Nephrol.* 2011; 6(11):2579-2586.
4. Pfeffer MA, Burdmann EA, Chen CY, et al. A trial of darbepoetin alfa in type 2 diabetes and chronic kidney disease. *N Engl J Med.* 2011; 361(21):2019-2032.
5. Gao S, Ma J-J, Lu C. Venous thromboembolism risk and erythropoiesis-stimulating agents for the treatment of cancer-associated anemia: a meta-analysis. *Tumor Biol.* 2013:1-11.
6. Elliot S, Tomita D, Endre Z. Erythropoiesis stimulating agents and reno-protection: a meta-analysis. *BMC Nephrology.* 2017;18:14.
7. Kang J, Park J, Lee JM, Park JJ, Choi D. The effects of erythropoiesis stimulating therapy for anemia in chronic heart failure: A meta-analysis of randomized clinical trials. *Int J of Cardiol.* 2016;12–22.
8. Wilhelm-Leen ER, Winkelmayr WC. Mortality Risk of Darbepoetin Alfa versus Epoetin Alfa in Patients with Chronic Kidney Disease: Systematic Review and Meta-Analysis. *Am J Kidney Dis.* 2015;69–74.
9. Patel S and Ohls RK. Darbepoetin administration in term and preterm neonates. *Clin Perinatol.* 2015;42(3): 557-566.
10. Castelli R, Sciara S, Delilieri GL, and Pantaleo G. Biosimilar epoetin alfa increases hemoglobin levels and brings cognitive and socio-relational benefits to elderly transfusion-dependent multiple myeloma patients: results from a pilot study. *Ann Hematol.* 2017;96:779-786.
11. Kalantar-Zadeh K. History of erythropoiesis-stimulating agents, the development of biosimilars, and the future of anemia treatment in nephrology. *Am J Nephrol.* 2017;45:235-247.
12. National Comprehensive Cancer Network (NCCN). NCCN Clinical Practice Guidelines in Oncology. Cancer-and-Chemotherapy-Induced Anemia. Version 2.2018. November 21, 2017.
13. National Comprehensive Cancer Network (NCCN). Epoetin alfa. NCCN Drugs and Biologics Compendium®. 2018.
14. National Comprehensive Cancer Network (NCCN). Darbepoietin alfa. NCCN Drugs and Biologics Compendium®. 2018.
15. Epoetin alfa. Micromedex®Solutions Compendia. 2018.
16. Darbepoietin alfa. Micromedex®Solutions Compendia. 2018.
17. Epoetin alfa-epbx. Micromedex®Solutions Compendia. 2018.

18. Methoxy polyethylene glycol-epoetin beta. Micromedex®Solutions Compendia. 2018.
19. Epoetin alfa. Clinical Pharmacology Compendia. Tampa FL: Gold Standard, Inc. 2018.
20. Darbepoietin-alfa. Clinical Pharmacology Compendia. Tampa FL: Gold Standard, Inc. 2018.
21. Methoxy polyethylene glycol-epoetin beta. Clinical Pharmacology Compendia. Tampa FL: Gold Standard, Inc. 2018.
22. Procrit® (epoetin alfa) injection, for intravenous or subcutaneous use [package insert]. Thousand Oaks, CA, Amgen Inc. Revised 09/2017.
23. Aranesp® (darbepoietin alfa) injection, for intravenous or subcutaneous use [package insert]. Thousand Oaks, CA, Amgen Inc. Revised 01/2018.
24. Retacrit™ (epoetin alfa-epbx) injection, for intravenous or subcutaneous use [package insert]. New York, NY, Pfizer Inc. Revised 06/2018.
25. Mircera® (methoxy polyethylene glycol-epoetin beta) injection, for intravenous or subcutaneous use [package insert]. South San Francisco, CA, Hoffmann-La Roche Inc. Revised 6/2018.